Frontier Capital Management Co. LLC Has $30.03 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Frontier Capital Management Co. LLC lowered its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 26.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 435,006 shares of the biopharmaceutical company's stock after selling 159,100 shares during the period. Frontier Capital Management Co. LLC owned 0.24% of Insmed worth $30,033,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC raised its stake in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management bought a new stake in Insmed in the 4th quarter valued at $47,000. Smartleaf Asset Management LLC raised its stake in Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 411 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Insmed during the 4th quarter worth $86,000.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the sale, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. This trade represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. The trade was a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 88,232 shares of company stock worth $6,868,473 over the last 90 days. Insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on INSM shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. JPMorgan Chase & Co. increased their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Jefferies Financial Group began coverage on Insmed in a research report on Tuesday. They issued a "buy" rating and a $105.00 price target on the stock. Finally, Morgan Stanley raised their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $94.63.

Insmed Price Performance

Insmed stock traded down $2.04 during midday trading on Tuesday, reaching $65.71. The company's stock had a trading volume of 2,154,822 shares, compared to its average volume of 2,324,370. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a 50-day moving average price of $72.17 and a 200-day moving average price of $73.26. The stock has a market cap of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same quarter in the prior year, the firm earned ($1.06) EPS. The business's revenue was up 22.9% on a year-over-year basis. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.